Physician profile
Darragh Gott
NPI 1194987396
$6,562.48
in general payments reported to CMS, 2019-2025
44 companies · $1,844 in 2025
The $1,844 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,192 · 2022: $794 · 2023: $1,325 · 2024: $1,406 · 2025: $1,844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,575.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,192.07 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $695.82 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $676.36 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $572.42 | 2021-2025 | |
| Lilly USA, LLC | $463.57 | 2021-2025 | Mounjaro, Lyumjev, Baqsimi |
| Amgen INC. | $431.21 | 2021-2025 | Repatha, Krystexxa, Otezla |
| Insulet Corporation | $262.29 | 2023-2025 | Omnipod, Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.01 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Nevro Corp. | $241.43 | 2022-2023 | Senza |
| Astellas Pharma US INC | $168.13 | 2023-2025 | Veozah |
| Eisai INC. | $161.00 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $125.55 | 2021 | |
| Daiichi Sankyo INC. | $124.72 | 2021 | |
| Scilex Pharmaceuticals INC. | $108.00 | 2022-2025 | Ztlido |
| Biohaven Pharmaceutical Holding Company LTD. | $91.58 | 2022 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $90.29 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $87.43 | 2025 | Auvelity, Symbravo |
| Sanofi-Aventis U.S. LLC | $71.74 | 2024 | |
| Aimmune Therapeutics, INC. | $65.96 | 2024-2025 | Zenpep |
| Inspire Medical Systems, INC. | $63.58 | 2023 | Inspire |
| Boston Scientific Corporation | $62.54 | 2024-2025 | General - Therapies |
| Lucid Diagnostics INC. | $47.03 | 2023-2025 | |
| Ibsa Pharma INC. | $41.90 | 2024-2025 | Licart, Tirosint, Flector |
| Cequr Corporation | $39.38 | 2024 | Cequr Simplicity |
| Exact Sciences Corporation | $34.81 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.63 | 2024 | Caplyta |
| Glaxosmithkline, LLC. | $29.89 | 2021-2025 | Shingrix, Bexsero, Arexvy |
| Antares Pharma, INC. | $28.58 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.66 | 2024-2025 | Xifaxan |
| Pulmonx Corporation | $22.30 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Grifols USA, LLC | $21.42 | 2025 | Prolastin-C Liquid |
| Abbott Laboratories | $20.44 | 2024 | Freestyle Libre 3 |
| Lundbeck LLC | $19.98 | 2023 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $18.72 | 2024 | Livalo |
| Nestle Healthcare Nutrition INC. | $18.46 | 2021 | |
| Bausch Health US, LLC | $18.27 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.74 | 2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $16.94 | 2023 | |
| Cleerly, INC. | $16.81 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Merck Sharp & Dohme LLC | $16.39 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $15.86 | 2022 | |
| Seqirus USA INC | $15.58 | 2024 | Flucelvax, Fluad |
| Idorsia Pharmaceuticals US INC | $14.45 | 2023 | Quviviq |
| Allergan, INC. | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darragh Gott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.